TY - JOUR T1 - Changes in Oxygen Saturation During Fiberoptic Bronchoscopy: High-Flow Nasal Cannula versus Standard Oxygen Therapy JF - Respiratory Care SP - 727 LP - 733 DO - 10.4187/respcare.10598 VL - 68 IS - 6 AU - Pedro Pablo Arias-Sanchez AU - Gabriela Ledesma AU - Johana Cobos AU - Hugo Tirape AU - Betzy Jaramillo AU - Jeimmy Ruiz AU - Lucia Pacheco AU - Juan Martinez AU - Remigio Maldonado AU - Luis Andrade AU - Omar Bustamante AU - Hernan Aguirre-Bermeo Y1 - 2023/06/01 UR - http://rc.rcjournal.com/content/68/6/727.abstract N2 - BACKGROUND: Hypoxemia is a relatively common complication in stable patients during fiberoptic bronchoscopy (FOB). To prevent this complication, high-flow nasal cannula (HFNC) has been described as an alternative to standard oxygen therapy. However, the advantages of HFNC over standard oxygen therapy in acute care patients receiving supplemental oxygen before FOB performed with an oral approach are unknown.METHODS: We conducted an observational study that involved subjects with a presumptive diagnosis of pneumonia and a clinical indication for a bronchial aspirate sample. The type of oxygen support (standard oxygen therapy vs HFNC) was selected according to availability. The oxygen flow in the HFNC group was 60 L/min. In both groups, the FIO2 was set at 0.40. Hemodynamic, respiratory dynamics, and gas exchange data were collected at baseline, before, during, and 24 h after FOB.RESULTS: Forty subjects were included, 20 in each group (HFNC and standard oxygen therapy). The study was performed on day 5 of hospitalization in the HFNC group and on day 4 in the standard oxygen therapy group (P = .10). No significant between-group differences in baseline characteristics were observed. HFNC vs standard oxygen therapy was associated with a smaller decrease in SpO2 levels during the procedure (94% vs 90%; P = .040, respectively) and with less variation between the last SpO2 measured before FOB and the lowest SpO2 during FOB (Δ SpO2): 2% versus 4.5% (P = .01, respectively).CONCLUSIONS: In acute subjects who required oxygen support before FOB, the use of HFNC during FOB with an oral approach was associated with a smaller decrease in SpO2 and lower Δ SpO2 compared with standard oxygen therapy. ER -